SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-000831
Filing Date
2017-02-23
Accepted
2017-02-23 09:43:52
Documents
14
Period of Report
2016-12-31

Document Format Files

Seq Description Document Type Size
1 20-F rdhl_currentfolio20-f.htm 20-F 3238996
2 EX-4.11 rdhl_ex411.htm EX-4.11 492569
3 EX-4.12 rdhl_ex412.htm EX-4.12 542013
4 EX-4.13 rdhl_ex413.htm EX-4.13 473387
5 EX-4.14 rdhl_ex414.htm EX-4.14 910877
6 EX-4.24 rdhl_ex424.htm EX-4.24 271291
7 EX-12.1 rdhl_ex121.htm EX-12.1 18507
8 EX-12.2 rdhl_ex122.htm EX-12.2 16376
9 EX-13 rdhl_ex13.htm EX-13 8844
10 EX-15.1 rdhl_ex151.htm EX-15.1 8630
11 GRAPHIC rdhlex412001.jpg GRAPHIC 6294
12 GRAPHIC rdhlex412002.jpg GRAPHIC 6141
13 GRAPHIC rdhlex151001.jpg GRAPHIC 2183
14 GRAPHIC rdhlcurrentfolio20f001.jpg GRAPHIC 2395
  Complete submission text file 0001558370-17-000831.txt   6006467
Mailing Address 21 HA'ARBA'A STREET TEL AVIV L3 64739
Business Address 21 HA'ARBA'A STREET TEL AVIV L3 64739 972-3-541-3131
RedHill Biopharma Ltd. (Filer) CIK: 0001553846 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 20-F | Act: 34 | File No.: 001-35773 | Film No.: 17631015
SIC: 2834 Pharmaceutical Preparations